Bridging the gap in cardiovascular care in diabetic patients: are cardioprotective antihyperglycemic agents underutilized?

References

• Joseph JJ, Deedwania P, Acharya T, et al. Comprehensive management of cardiovascular risk factors for adults with type 2 diabetes: a scientific statement from the American heart Association. Circulation. 2022;145(9):e722–e59. doi: 10.1161/CIR.0000000000001040
   PubMed Web of Science ®Google Scholar
• Cefalu WT, Kaul S, Gerstein HC, et al. Cardiovascular Outcomes Trials in Type 2 Diabetes: Where Do We Go From Here? Reflections From a Diabetes Care Editors’ Expert Forum. Dia Care. 2018;41(1):14–31. doi: 10.2337/dci17-0057
   PubMed Web of Science ®Google Scholar
• Ghosh-Swaby OR, Goodman SG, Leiter LA, et al. Glucose-lowering drugs or strategies, atherosclerotic cardiovascular events, and heart failure in people with or at risk of type 2 diabetes: an updated systematic review and meta-analysis of randomised cardiovascular outcome trials. Lancet Diabetes Endocrinol. 2020;8(5):418–435. doi: 10.1016/S2213-8587(20)30038-3
   PubMed Web of Science ®Google Scholar
• Wright AK, Carr MJ, Kontopantelis E, et al. Primary prevention of cardiovascular and heart failure events with SGLT2 inhibitors, GLP-1 receptor agonists, and their combination in type 2 diabetes. Diabetes Care. 2022;45(4):909–918. doi: 10.2337/dc21-1113
   PubMed Web of Science ®Google Scholar
• Scheen AJ. Clinical pharmacology of antidiabetic drugs: what can be expected of their use? Presse Med. 2022;52(1):104158. doi: 10.1016/j.lpm.2022.104158
   PubMed Web of Science ®Google Scholar
• Das SR, Everett BM, Birtcher KK, et al. Expert consensus decision pathway on novel therapies for cardiovascular risk reduction in patients with type 2 diabetes: a report of the American College of cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2020;76(9):1117–1145. doi: 10.1016/j.jacc.2020.05.037
   PubMed Web of Science ®Google Scholar
• Brown E, Heerspink HJL, Cuthbertson DJ, et al. SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications. Lancet. 2021;398(10296):262–276. doi: 10.1016/S0140-6736(21)00536-5
   PubMed Web of Science ®Google Scholar
• Marx N, Davies MJ, Grant PJ, et al. Guideline recommendations and the positioning of newer drugs in type 2 diabetes care. Lancet Diabetes Endocrinol. 2021;9(1):46–52. doi: 10.1016/S2213-8587(20)30343-0
   PubMed Web of Science ®Google Scholar
• Davies MJ, Aroda VR, Collins BS, et al. Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American diabetes Association (ADA) and the European Association for the study of diabetes (EASD). Diabetologia. 2022;65(12):1925–1966. doi: 10.1007/s00125-022-05787-2
   PubMed Web of Science ®Google Scholar
• Samson SL, Vellanki P, Blonde L, et al. American Association of clinical Endocrinology consensus statement: comprehensive type 2 diabetes management algorithm – 2023 update. Endocr Pract. 2023;29(5):305–340. doi: 10.1016/j.eprac.2023.02.001
   PubMed Web of Science ®Google Scholar
• Lim CE, Pasternak B, Eliasson B, et al. Use of sodium–glucose co-transporter 2 inhibitors and glucagon-like peptide-1 receptor agonists according to the 2019 ESC guidelines and the 2019 ADA/EASD consensus report in a national population of patients with type 2 diabetes. Eur J Prevent Cardiol. 2023;30(8):634–643. doi: 10.1093/eurjpc/zwac315
   PubMed Web of Science ®Google Scholar
• McCoy RG, Van Houten HK, Karaca-Mandic P, et al. Second-line therapy for type 2 diabetes management: the treatment/benefit paradox of cardiovascular and kidney comorbidities. Diabetes Care. 2021;44:2302–2311. doi: 10.2337/dc20-2977
   PubMed Web of Science ®Google Scholar
• Sattar N, Lee MMY, Kristensen SL, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. Lancet Diabetes Endocrinol. 2021;9(10):653–662. doi: 10.1016/S2213-8587(21)00203-5
   PubMed Web of Science ®Google Scholar
• Giugliano D, Longo M, Signoriello S, et al. The effect of DPP-4 inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors on cardiorenal outcomes: a network meta-analysis of 23 CVOTs. Cardiovasc Diabetol. 2022;21(1):42. doi: 10.1186/s12933-022-01474-z
   PubMed Web of Science ®Google Scholar
• Marx N, Husain M, Lehrke M, et al. GLP-1 receptor agonists for the reduction of atherosclerotic cardiovascular risk in patients with type 2 diabetes. Circulation. 2022;146(24):1882–1894. doi: 10.1161/CIRCULATIONAHA.122.059595
   PubMed Web of Science ®Google Scholar
• Wu Q, Li D, Huang C, et al. Glucose control independent mechanisms involved in the cardiovascular benefits of glucagon-like peptide-1 receptor agonists. Biomed Pharmacother. 2022;153:113517. doi: 10.1016/j.biopha.2022.113517
   PubMed Web of Science ®Google Scholar
• Marx N, Federici M, Schütt K, et al.; ESC Scientific Document Group. ESC guidelines for the management of cardiovascular disease in patients with diabetes. Eur Heart J 2023 Aug;25: ehad192. doi: 10.1093/eurheartj/ehad192.
   Google Scholar
• Rahman A, Alqaisi S, Saith SE, et al. The impact of glucagon-like peptide-1 receptor agonist on the cardiovascular outcomes in patients with type 2 diabetes mellitus: a meta-analysis and systematic review. Cardiol Res. 2023;14(4):250–260. doi: 10.14740/cr1523
   PubMed Web of Science ®Google Scholar
• Mahtta D, Ramsey DJ, Lee MT, et al. Utilization rates of SGLT2 inhibitors and GLP-1 receptor agonists and their facility-level variation among patients with atherosclerotic cardiovascular disease and type 2 diabetes: insights from the department of Veterans Affairs. Diabetes Care. 2022;45(2):372–380. doi: 10.2337/dc21-1815
   PubMed Web of Science ®Google Scholar
• Devineni D, Akbarpour M, Gong Y, et al. Inadequate use of newer treatments and glycemic control by cardiovascular risk and sociodemographic groups in US adults with diabetes in the NIH Precision Medicine Initiative all of Us Research Program. Cardiovasc Drugs Ther. 2022 Nov 15; published on line. doi: 10.1007/s10557-022-07403-2
   PubMed Web of Science ®Google Scholar
• Hao R, Myroniuk T, McGuckin T, et al. Underuse of cardiorenal protective agents in high-risk diabetes patients in primary care: a cross-sectional study. BMC Prim Care. 2022;23(1):124. doi: 10.1186/s12875-022-01731-w
   PubMedGoogle Scholar
• Honigberg MC, Chang LS, McGuire DK, et al. Use of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes and cardiovascular disease: a review. JAMA Cardiol. 2020;5(10):1182–1190. doi: 10.1001/jamacardio.2020.1966
   PubMed Web of Science ®Google Scholar
• Zheng C, Lin M, Chen Y, et al. Effects of sodium-glucose cotransporter type 2 inhibitors on cardiovascular, renal, and safety outcomes in patients with cardiovascular disease: a meta-analysis of randomized controlled trials. Cardiovasc Diabetol. 2021;20(1):83. doi: 10.1186/s12933-021-01272-z
   PubMed Web of Science ®Google Scholar
• Gager GM, Gelbenegger G, Jilma B, et al. Cardiovascular outcome in patients treated with SGLT2 inhibitors for heart failure: a meta-analysis. Front Cardiovasc Med. 2021;8:691907. doi: 10.3389/fcvm.2021.691907
   PubMedGoogle Scholar
• Inzucchi SE, Kosiborod M, Fitchett D, et al. Improvement in cardiovascular outcomes with empagliflozin is independent of glycemic control. Circulation. 2018;138(17):1904–1907. doi: 10.1161/CIRCULATIONAHA.118.035759
   PubMed Web of Science ®Google Scholar
• Cowie MR, Fisher M. SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control. Nat Rev Cardiol. 2020;17(12):761–772. doi: 10.1038/s41569-020-0406-8
   PubMed Web of Science ®Google Scholar
• Li CX, Liang S, Gao L, et al. Cardiovascular outcomes associated with SGLT-2 inhibitors versus other glucose-lowering drugs in patients with type 2 diabetes: a real-world systematic review and meta-analysis. PLoS One. 2021;16(2):e0244689. doi: 10.1371/journal.pone.0244689
   PubMed Web of Science ®Google Scholar
• Hinton W, Ansari AS, Whyte MB, et al. Sodium-glucose co-transporter-2 inhibitors in type 2 diabetes: are clinical trial benefits for heart failure reflected in real-world clinical practice? A systematic review and meta-analysis of observational studies. Diab Obes Metab. 2023;25(2):501–515. doi: 10.1111/dom.14893
   PubMed Web of Science ®Google Scholar
• Hussain A, Ramsey D, Lee M, et al. Utilization rates of SGLT2 inhibitors among patients with type 2 diabetes, heart failure, and atherosclerotic cardiovascular disease: insights from the department of Veterans Affairs. JACC Heart Fail. 2023;11(8):933–942. doi: 10.1016/j.jchf.2023.03.024
   PubMed Web of Science ®Google Scholar
• Ozaki AF, Ko DT, Chong A, et al. Prescribing patterns and factors associated with sodium–glucose cotransporter-2 inhibitor prescribing in patients with diabetes mellitus and atherosclerotic cardiovascular disease. CMAJ Open. 2023;11(3):E494–E503. doi: 10.9778/cmajo.20220039
   PubMedGoogle Scholar
• Nargesi AA, Jeyashanmugaraja GP, Desai N, et al. Contemporary national patterns of eligibility and use of novel cardioprotective antihyperglycemic agents in type 2 diabetes mellitus. J Am Heart Assoc. 2021;10(13):e021084. doi: 10.1161/JAHA.121.021084
   PubMed Web of Science ®Google Scholar
• Nelson AJ, Ardissino M, Haynes K, et al. Gaps in evidence-based therapy use in insured patients in the United States with type 2 diabetes mellitus and atherosclerotic cardiovascular disease. J Am Heart Assoc. 2021;10(2):e016835. doi: 10.1161/JAHA.120.016835
   PubMed Web of Science ®Google Scholar
• Nelson AJ, O’Brien EC, Kaltenbach LA, et al. Use of lipid-, blood pressure–, and glucose-lowering pharmacotherapy in patients with type 2 diabetes and atherosclerotic cardiovascular disease. JAMA Netw Open. 2022;5(2):e2148030. doi: 10.1001/jamanetworkopen.2021.48030
   PubMed Web of Science ®Google Scholar
• Zhai MZ, Avorn J, Liu J, et al. Variations in use of diabetes drugs with cardiovascular benefits among medicaid patients. JAMA Netw Open. 2022;5:e2240117. doi: 10.1001/jamanetworkopen.2022.40117
   PubMed Web of Science ®Google Scholar
• Eberly LA, Yang L, Essien UR, et al. Racial, ethnic, and socioeconomic inequities in glucagon-like peptide-1 receptor agonist use among patients with diabetes in the US. JAMA Health Forum. 2021;2(12):e214182. doi: 10.1001/jamahealthforum.2021.4182
   PubMedGoogle Scholar
• Khunti K, Jabbour S, Cos X, et al. Sodium-glucose co-transporter-2 inhibitors in patients with type 2 diabetes: barriers and solutions for improving uptake in routine clinical practice. Diab Obes Metab. 2022;24(7):1187–1196. doi: 10.1111/dom.14684
   PubMed Web of Science ®Google Scholar
• Bidulka P, Mathur R, Lugo-Palacios DG, et al. Ethnic and socioeconomic disparities in initiation of second-line antidiabetic treatment for people with type 2 diabetes in England: a cross-sectional study. Diab Obes Metab. 2023;25(1):282–292. doi: 10.1111/dom.14874
   PubMed Web of Science ®Google Scholar
• Falkentoft AC, Andersen J, Malik ME, et al. Impact of socioeconomic position on initiation of SGLT-2 inhibitors or GLP-1 receptor agonists in patients with type 2 diabetes - a Danish nationwide observational study. Lancet Reg Health Eur. 2022;14:100308. doi: 10.1016/j.lanepe.2022.100308
   PubMedGoogle Scholar
• Karagiannis T, Bekiari E, Tsapas A. Socioeconomic aspects of incretin-based therapy. Diabetologia. 2023;66(10):1859–1868. doi: 10.1007/s00125-023-05962-z
   PubMed Web of Science ®Google Scholar
• Arnold SV, Tang F, Cooper A, et al. Global use of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes Results from discover. BMC Endocr Disord. 2022;22(1):111. doi: 10.1186/s12902-022-01026-2
   PubMed Web of Science ®Google Scholar
• Hanna J, Nargesi AA, Essien UR, et al. County-level variation in cardioprotective antihyperglycemic prescribing among medicare beneficiaries. Am J Prev Cardiol. 2022;11:100370. doi: 10.1016/j.ajpc.2022.100370
   PubMedGoogle Scholar
• Nelson AJ, Pagidipati NJ, Aroda VR, et al. Incorporating SGLT2i and GLP-1RA for cardiovascular and kidney disease risk reduction: call for action to the cardiology community. Circulation. 2021;144(1):74–84. doi: 10.1161/CIRCULATIONAHA.121.053766
   PubMed Web of Science ®Google Scholar
• Scheen AJ. Underuse of glucose-lowering medications associated with cardiorenal protection in type 2 diabetes: from delayed initiation to untimely discontinuation. Lancet Reg Health Eur. 2023;29:100627.
   PubMedGoogle Scholar
• Chew BH, Mohd-Yusof BN, Lai PSM, et al. Overcoming therapeutic inertia as the achilles’ heel for improving suboptimal diabetes care: an integrative review. Endocrinol Metab. 2023;38(1):34–42. doi: 10.3803/EnM.2022.1649
   Google Scholar
• Schernthaner G, Shehadeh N, Ametov AS, et al. Worldwide inertia to the use of cardiorenal protective glucose-lowering drugs (SGLT2i and GLP-1 RA) in high-risk patients with type 2 diabetes. Cardiovasc Diabetol. 2020;19:185. doi: 10.1186/s12933-020-01154-w
   PubMed Web of Science ®Google Scholar
• Scheen AJ. Cardiovascular and renal protection with sodium-glucose cotransporter type 2 inhibitors: new paradigm in type 2 diabetes management…and potentially beyond. Ann Transl Med. 2019;7:S132. doi: 10.21037/atm.2019.05.82
   PubMed Web of Science ®Google Scholar
• Davies MJ, Drexel H, Jornayvaz FR, et al. Cardiovascular outcomes trials: a paradigm shift in the current management of type 2 diabetes. Cardiovasc Diabetol. 2022;21(1):144. doi: 10.1186/s12933-022-01575-9
   PubMed Web of Science ®Google Scholar
• Jacob S, Krentz AJ, Deanfield J, et al. Evolution of type 2 diabetes management from a glucocentric approach to cardio-renal risk reduction: the new paradigm of care. Drugs. 2021;81(12):1373–1379. doi: 10.1007/s40265-021-01554-6
   PubMed Web of Science ®Google Scholar
• Gao Y, Peterson E, Pagidipati N. Barriers to prescribing glucose-lowering therapies with cardiometabolic benefits. Am Heart J. 2020;224:47–53. doi: 10.1016/j.ahj.2020.03.017
   PubMed Web of Science ®Google Scholar
• Pagidipati NJ, Nelson AJ, Kaltenbach LA, et al. Coordinated care to optimize cardiovascular preventive therapies in type 2 diabetes: a randomized clinical trial. JAMA. 2023;329(15):1261–1270. doi: 10.1001/jama.2023.2854
   PubMed Web of Science ®Google Scholar
• Malik ME, Falkentoft AC, Jensen J, et al. Discontinuation and reinitiation of SGLT-2 inhibitors and GLP-1R agonists in patients with type 2 diabetes: a nationwide study from 2013 to 2021. Lancet Reg Health Eur. 2023;29:100617. doi: 10.1016/j.lanepe.2023.100617
   PubMedGoogle Scholar
• Mustafa OG, Whyte MB. The use of GLP-1 receptor agonists in hospitalised patients: an untapped potential. Diabetes Metab Res Rev. 2019;35:e3191. doi: 10.1002/dmrr.3191
   PubMed Web of Science ®Google Scholar
• Demidowich AP, Batty K, Zilbermint M. Instituting a successful discharge plan for patients with type 2 diabetes: challenges and solutions. Diabetes Spectr. 2022;35(4):440–451. doi: 10.2337/dsi22-0013
   PubMedGoogle Scholar
• Pierce JB, Vaduganathan M, Fonarow GC, et al. Contemporary use of sodium-glucose cotransporter-2 inhibitor therapy among patients hospitalized for heart failure with reduced ejection fraction in the US: the get with the guidelines-heart failure registry. JAMA Cardiol. 2023;8(7):652–661. doi: 10.1001/jamacardio.2023.1266
   PubMed Web of Science ®Google Scholar
• Ferro EG, Pitt B, Bhatt DL. SGLT-2 inhibitors in heart failure: time for broader eligibility and earlier initiation. Cleve Clin J Med. 2021;88(11):601–606. doi: 10.3949/ccjm.88a.21045
   PubMed Web of Science ®Google Scholar
• Norgard NB, Lopez-Candales A. The rise of SGLT2 inhibitors: the time is now for cardiovascular specialists to lead the charge. Postgrad Med. 2022;134(1):11–13. doi: 10.1080/00325481.2021.2002580
   PubMed Web of Science ®Google Scholar
• Ofori-Asenso R, Sahle BW, Chin KL, et al. Poor adherence and persistence to sodium glucose co-transporter 2 inhibitors in real-world settings: evidence from a systematic review and meta-analysis. Diabetes Metab Res Rev. 2021;37:e3350. doi: 10.1002/dmrr.3350
   PubMed Web of Science ®Google Scholar
• Alkabbani W, Shah BR, Zongo A, et al. Post-initiation predictors of discontinuation of the sodium-glucose cotransporter-2 inhibitors: a comparative cohort study from the United Kingdom. Diab Obes Metab. 2023. published on line. doi: 10.1111/dom.15241
   PubMed Web of Science ®Google Scholar
• Weiss T, Carr RD, Pal S, et al. Real-world adherence and discontinuation of glucagon-like peptide-1 receptor agonists therapy in type 2 diabetes mellitus patients in the United States. Patient Prefer Adherence. 2020;14:2337–2345. doi: 10.2147/PPA.S277676
   PubMed Web of Science ®Google Scholar
• Palanca A, Ampudia-Blasco FJ, Calderon JM, et al. Real-world evaluation of GLP-1 receptor agonist therapy persistence, adherence and therapeutic inertia among obese adults with type 2 diabetes. Diabetes Ther. 2023;14(4):723–736. doi: 10.1007/s13300-023-01382-9
   PubMed Web of Science ®Google Scholar
• Lee DSU, Lee H. Adherence and persistence rates of major antidiabetic medications: a review. Diabetol Metab Syndr. 2022;14(1):12. doi: 10.1186/s13098-022-00785-1
   PubMed Web of Science ®Google Scholar
• Sikirica MV, Martin AA, Wood R, et al. Reasons for discontinuation of GLP1 receptor agonists: data from a real-world cross-sectional survey of physicians and their patients with type 2 diabetes. Diabetes Metab Syndr Obes. 2017;10:403–412. doi: 10.2147/DMSO.S141235
   PubMed Web of Science ®Google Scholar
• Byrne J, Willis A, Dunkley A, et al. Individual, healthcare professional and system-level barriers and facilitators to initiation and adherence to injectable therapies for type 2 diabetes: a systematic review and meta-ethnography. Diabet Med. 2022;39:e14678. doi: 10.1111/dme.14678
   PubMed Web of Science ®Google Scholar
• Dave CV, Schneeweiss S, Wexler DJ, et al. Trends in clinical characteristics and prescribing preferences for SGLT2 inhibitors and GLP-1 receptor agonists, 2013–2018. Diabetes Care. 2020;43(4):921–924. doi: 10.2337/dc19-1943
   PubMed Web of Science ®Google Scholar
• Weeda ER, Muraoka AK, Brock MD, et al. Medication adherence to injectable glucagon-like peptide-1 (GLP-1) receptor agonists dosed once weekly vs once daily in patients with type 2 diabetes: a meta-analysis. Int J Clin Pract. 2021;75:e14060. doi: 10.1111/ijcp.14060
   PubMed Web of Science ®Google Scholar
• Isaacs DM, Kruger DF, Spollett GR. Optimizing therapeutic outcomes with oral semaglutide: a patient-centered approach. Diabetes Spectr. 2021;34(1):7–19. doi: 10.2337/ds20-0016
   PubMedGoogle Scholar
• Luo J, Feldman R, Callaway Kim K, et al. Evaluation of out-of-pocket costs and treatment intensification with an SGLT2 inhibitor or GLP-1 RA in patients with type 2 diabetes and cardiovascular disease. JAMA Netw Open. 2023;6(6):e2317886. doi: 10.1001/jamanetworkopen.2023.17886
   PubMed Web of Science ®Google Scholar
• Essien UR, Singh B, Swabe G, et al. Association of prescription co-payment with adherence to glucagon-like peptide-1 receptor agonist and sodium-glucose cotransporter-2 inhibitor therapies in patients with heart failure and diabetes. JAMA Netw Open. 2023;6:e2316290. doi: 10.1001/jamanetworkopen.2023.16290
   PubMed Web of Science ®Google Scholar
• Consoli A, Formoso G. Potential side effects to GLP-1 agonists: understanding their safety and tolerability. Expert Opin Drug Saf. 2015;14(2):207–218. doi: 10.1517/14740338.2015.987122
   PubMed Web of Science ®Google Scholar
• Scheen AJ. SGLT2 inhibitors: benefit/risk balance. Curr Diab Rep. 2016;16(10):92. doi: 10.1007/s11892-016-0789-4
   PubMed Web of Science ®Google Scholar
• Scheen AJ. An update on the safety of SGLT2 inhibitors. Expert Opin Drug Safety. 2019;18(4):295–311. doi: 10.1080/14740338.2019.1602116
   PubMed Web of Science ®Google Scholar
• Hong D, Si L, Jiang M, et al. Cost effectiveness of sodium-glucose cotransporter-2 (SGLT2) inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonists, and dipeptidyl peptidase-4 (DPP-4) inhibitors: a systematic review. PharmacoEconomics. 2019;37(12):777–818. doi: 10.1007/s40273-019-00833-1
   PubMed Web of Science ®Google Scholar
• McEwan P, Bennett H, Khunti K, et al. Assessing the cost-effectiveness of sodium–glucose cotransporter-2 inhibitors in type 2 diabetes mellitus: a comprehensive economic evaluation using clinical trial and real-world evidence. Diab Obes Metab. 2020;22(12):2364–2374. doi: 10.1111/dom.14162
   PubMed Web of Science ®Google Scholar
• Morton JI, Marquina C, Shaw JE, et al. Projecting the incidence and costs of major cardiovascular and kidney complications of type 2 diabetes with widespread SGLT2i and GLP-1 RA use: a cost-effectiveness analysis. Diabetologia. 2023;66(4):642–656. doi: 10.1007/s00125-022-05832-0
   PubMed Web of Science ®Google Scholar
• Ferrannini E, Rosenstock J. Clinical translation of cardiovascular outcome trials in type 2 diabetes: is there more or is there less than meets the eye? Diabetes Care. 2021;44(3):641–646. doi: 10.2337/dc20-0913
   PubMed Web of Science ®Google Scholar
• Scheen AJ. Series: implications of the recent CVOTs in type 2 diabetes: impact on guidelines: the endocrinologist point of view. Diabet Res Clin Pract. 2020;159:107726. doi: 10.1016/j.diabres.2019.05.005
   PubMed Web of Science ®Google Scholar
• Rasalam R, Abdo S, Deed G, et al. Early type 2 diabetes treatment intensification with glucagon-like peptide-1 receptor agonists in primary care: an Australian perspective on guidelines and the global evidence. Diab Obes Metab. 2023;25(4):901–915. doi: 10.1111/dom.14953
   PubMed Web of Science ®Google Scholar
• McEwan P, Foos V, Martin B, et al. Estimating the value of sodium-glucose cotransporter-2 inhibitors within the context of contemporary guidelines and the totality of evidence. Diab Obes Metab. 2023;25(7):1830–1838. doi: 10.1111/dom.15040
   PubMed Web of Science ®Google Scholar
• Sandhu AT, Cohen DJ. Cost-effectiveness of sodium-glucose cotransporter-2 inhibitors for patients with heart failure and preserved ejection fraction—living on the edge. JAMA Cardiol. 2023;8(5):415–416. doi: 10.1001/jamacardio.2023.0087
   PubMed Web of Science ®Google Scholar